MANKIND PHARMA
|
MANKIND PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 46.34 | 48.25 | 47.75 | 32.00 | 35.78 |
| CEPS(Rs) | 68.42 | 63.69 | 57.89 | 40.83 | 40.43 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 393.72 | 346.31 | 233.15 | 185.61 | 153.65 |
| Tax Rate(%) | 16.92 | 20.26 | 19.06 | 21.63 | 26.42 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 24.25 | 23.82 | 23.56 | 20.89 | 24.66 |
| EBIT Margin(%) | 19.93 | 23.25 | 22.78 | 18.86 | 25.21 |
| Pre Tax Margin(%) | 15.62 | 19.85 | 22.46 | 18.35 | 24.47 |
| PAT Margin (%) | 12.98 | 15.83 | 18.18 | 14.38 | 18.00 |
| Cash Profit Margin (%) | 18.91 | 20.73 | 21.72 | 17.96 | 20.07 |
| Performance Ratios | |||||
| ROA(%) | 7.00 | 10.15 | 18.00 | 13.94 | 18.83 |
| ROE(%) | 12.69 | 16.98 | 23.14 | 19.27 | 26.72 |
| ROCE(%) | 13.24 | 18.32 | 28.35 | 23.49 | 33.96 |
| Asset Turnover(x) | 0.54 | 0.64 | 0.99 | 0.97 | 1.05 |
| Sales/Fixed Asset(x) | 0.71 | 0.95 | 1.92 | 1.92 | 2.52 |
| Working Capital/Sales(x) | 33.62 | 9.59 | 2.40 | 3.70 | 4.53 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.42 | 1.06 | 0.52 | 0.52 | 0.40 |
| Receivable days | 39.93 | 34.35 | 24.35 | 19.33 | 16.25 |
| Inventory Days | 51.78 | 52.50 | 52.16 | 65.31 | 66.57 |
| Payable days | 111.46 | 99.93 | 101.86 | 130.57 | 131.38 |
| Valuation Parameters | |||||
| PER(x) | 43.29 | 50.22 | 48.11 | - | - |
| PCE(x) | 29.32 | 38.05 | 39.68 | - | - |
| Price/Book(x) | 5.09 | 7.00 | 9.85 | - | - |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 6.19 | 8.82 | 8.92 | -0.03 | 0.06 |
| EV/Core EBITDA(x) | 22.19 | 30.28 | 32.74 | -0.12 | 0.23 |
| EV/EBIT(x) | 29.68 | 36.54 | 37.63 | -0.15 | 0.25 |
| EV/CE(x) | 3.96 | 4.76 | 9.57 | -0.03 | 0.06 |
| M Cap / Sales | 5.80 | 8.19 | 8.97 | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 16.96 | 18.98 | 17.27 | 12.44 | 25.22 |
| Core EBITDA Growth(%) | 11.92 | 27.25 | 37.67 | -7.14 | 20.14 |
| EBIT Growth(%) | 0.97 | 21.22 | 41.65 | -15.60 | 18.78 |
| PAT Growth(%) | -3.41 | 3.39 | 48.19 | -9.86 | 12.37 |
| EPS Growth(%) | -3.97 | 1.05 | 49.22 | -10.58 | 13.28 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.37 | 0.58 | 0.02 | 0.02 | 0.14 |
| Current Ratio(x) | 1.07 | 1.23 | 3.10 | 2.32 | 1.68 |
| Quick Ratio(x) | 0.74 | 0.86 | 2.36 | 1.52 | 1.01 |
| Interest Cover(x) | 4.62 | 6.83 | 71.03 | 37.52 | 34.02 |
| Total Debt/Mcap(x) | 0.07 | 0.08 | - | - | - |
Compare Financial Ratios of peers of MANKIND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MANKIND PHARMA | ₹105,108.5 Cr | 0.8% | 8% | 0.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹467,870.0 Cr | 0.8% | 8.3% | 17.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹194,316.0 Cr | 7.1% | 9% | 4.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹169,316.0 Cr | 2% | 12.1% | 49.6% | Stock Analytics | |
| CIPLA | ₹115,477.0 Cr | -0.7% | 4.1% | -3.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹102,156.0 Cr | -1.7% | -4.2% | -3.1% | Stock Analytics | |
MANKIND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MANKIND PHARMA | 0.8% |
8% |
0.8% |
| SENSEX | 0.6% |
1.2% |
-7.8% |
You may also like the below Video Courses
